Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $389,585.16 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,017,271.63. This represents a 11.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Friday, February 14th, Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $255.17, for a total value of $398,320.37.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ ALNY opened at $252.49 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The business’s 50 day moving average price is $254.04 and its 200-day moving average price is $263.12. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a market cap of $32.69 billion, a price-to-earnings ratio of -116.36 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $637,000. Focus Partners Advisor Solutions LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $203,000. Worldquant Millennium Advisors LLC grew its stake in Alnylam Pharmaceuticals by 156.6% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after purchasing an additional 91,671 shares in the last quarter. Zurich Insurance Group Ltd FI bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $6,583,000. Finally, Vident Advisory LLC grew its stake in Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 232 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday. Scotiabank decreased their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research report on Friday, February 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Barclays boosted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.